Cosette debuts generic Compazine

Cosette is rolling out prochlorperazine edisylate injection in a dosage strength of 10 mg/2 ml (5 mg/ml).

The medication, which is the generic of Compazine, is used to control severe nausea and vomiting, as well as to treat schizophrenia.

[Read more: Solaris obtains FDA green light for generic Clindagel]

“This is the first injectable product Cosette has marketed in the U.S. and further exemplifies our strategy to expand and diversify Cosette’s portfolio of offerings,” Apurva Saraf, Cosette’s president and CEO, said. 

Prochlorperazine edisylate had a market value of roughly $15 million for the 12 months ending December 2021, according to IQVIA.

[Read More: Nexus Pharmaceuticals gets FDA nod for generic Compazine]

“This in-licensed product, along with our recent acquisition of eight branded products from Daiichi Sankyo, delivers on our goal of supplementing our internal R&D efforts by acquiring and integrating strategically aligned product portfolios into our business, allowing Cosette to bring an array of new and important medications to U.S. patients and prescribers,” Saraf said.